In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.).
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2012) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: